By Bl Mumbai Bureau

Copyright thehindubusinessline

Pharmaceutical stocks staged a recovery in Thursday’s morning session following the Federal Reserve’s 25 basis point rate cut, with the Nifty Pharma index climbing 138.70 points to 22,380.05, marking a 0.62 per cent gain from its previous close of 22,241.35. The sector witnessed broad-based buying with 14 stocks advancing against 6 declines, reversing Wednesday’s profit-booking trend.

Natco Pharma emerged as the top performer, surging 3.92 per cent to ₹890.85, followed by Biocon which gained 2.27 per cent to ₹362.40. Gland Pharma rose 1.76 per cent to ₹2,021.90, while Glenmark Pharmaceuticals advanced 1.38 per cent to ₹2,070.60, recovering from Wednesday’s decline when the stock faced selling pressure along with other pharma counters. Sun Pharma and Aurobindo Pharma also contributed positively with gains of 1.04 per cent and 0.89 per cent respectively.

The Fed’s dovish stance is expected to attract foreign capital to emerging markets including India, potentially strengthening the rupee and benefiting stock indices. Rajesh Palviya, SVP – Research at Axis Securities, noted that the rate cut reflects a cautious approach to supporting the labour market and could lead to gains in equities across sectors.

Trading activity remained robust in the pharma space, with Biocon leading volume charts at 49.91 lakh shares traded, generating a value of ₹180.25 crores. The sector’s recovery comes after Wednesday’s session where metals, FMCG, and pharma witnessed profit-taking according to market analysts.

Published on September 18, 2025